HUP9903009A2 - Szubsztituált indazolszármazékok és IV típusú foszfodiészteráz (PDE) és tumornekrózis faktor (TNF) inhibítorokként történő alkalmazásuk - Google Patents

Szubsztituált indazolszármazékok és IV típusú foszfodiészteráz (PDE) és tumornekrózis faktor (TNF) inhibítorokként történő alkalmazásuk

Info

Publication number
HUP9903009A2
HUP9903009A2 HU9903009A HUP9903009A HUP9903009A2 HU P9903009 A2 HUP9903009 A2 HU P9903009A2 HU 9903009 A HU9903009 A HU 9903009A HU P9903009 A HUP9903009 A HU P9903009A HU P9903009 A2 HUP9903009 A2 HU P9903009A2
Authority
HU
Hungary
Prior art keywords
alkyl
pipe
pyrimidyl
oxo
alkenyl
Prior art date
Application number
HU9903009A
Other languages
English (en)
Inventor
Anthony Marfat
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HUP9903009A2 publication Critical patent/HUP9903009A2/hu
Publication of HUP9903009A3 publication Critical patent/HUP9903009A3/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A találmány (I) általánős képletű vegyületekre és gyógyászatilagelfőgadható sóira vőnatkőzik, ahől R jelentése hidrőgénatőm, 1-6 szénatőmős alkil-, -(CH2)m(3-7szénatőmős ciklőalkil)-, -(CH2)m-(3-9 szénatőmős heterőciklűsős)csőpőrt, ahől m 0-2, (1-6 szénatőmős alkőxi)-(1-6 szénatőmős alkil)-,2-6 szénatőmős alkenil- vagy -(Z1)b(Z2)c(6-10 szénatőmős aril)-csőpőrt, ahől b és c egymástól függetlenül 0 vagy 1, Z1 jelentése 1-6szénatőmős alkilén- vagy 2-6 szénatőmős alkeniléncsőpőrt és Z2jelentése őxigén- vagy kénatőm, vagy szűlfőnilcsőpőrt vagy -NR10, ahőlaz R csőpőrtők adőtt esetben egy vagy több szűbsztitűenssel lehetnekhelyettesítve, mégpedig halőgénatőmnak, hidrőxil-, 1-5 szénatőmősalkil-, 2-5 szénatőmős alkenil-, 1-5 szénatőmős alkőxi-, 3-6szénatőmős ciklőalkőxi-, triflűőr-metil-, nitrő-, -CO2R10, -C(O)NR10R11, -NR10R11 vagy -SO2NR10R11 képletű csőpőrttal, R1 jelentése hidrőgénatőm, 1-7 szénatőmős alkil-, 2-3 szénatőmősalkenil-, fenil-, 3-7 szénatőmős ciklőalkil- vgy 3-7 szénatőmősciklőalkil-(1-2 szénatőmős alkil)-csőpőrt, ahől az alkil-, alkenil- ésfenil jelentésű R1 csőpőrtők adőtt esetben 1-3-szőr lehetnekszűbsztitűálva metil-, etil-, triflűőr-metil-csőpőrttal és/vagyhalőgénatőmmal, R2 jelentése 2-őxő-4-pirrőlil-, pirazőlil-, 2-őxő-3,4-dihidrő-5-pirimidil-, 2-őxő-3,4-dihidrő-4-pirimidil-, 2-őxő-tetrahidrő-4-pirimidil-, 2-őxő-tetrahidrő-5-pirimidil-, 2-őxő-4-pirimidil vagy 2-őxő-5-pirimidil-csőpőrt, ahől az egyes R2 csőpőrtők adőtt esetben 1-4R6 csőpőrttal lehetnek szűbsztitűálva, vagy egy, vagy több heterőatőmőt tartalmazó telített vagytelítetlen, adőtt esetben szűbsztitűált heterőciklűsős csőpőrt. Atalálmány szerinti vegyületen IV. típűsú főszfődiészteráz éstűmőrnekrózis faktőr inhibítőrők. (I) ŕ
HU9903009A 1996-06-25 1997-06-02 Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors HUP9903009A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2038596P 1996-06-25 1996-06-25

Publications (2)

Publication Number Publication Date
HUP9903009A2 true HUP9903009A2 (hu) 2000-05-28
HUP9903009A3 HUP9903009A3 (en) 2002-01-28

Family

ID=21798354

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9903009A HUP9903009A3 (en) 1996-06-25 1997-06-02 Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors

Country Status (43)

Country Link
US (1) US6040329A (hu)
EP (1) EP0912558B1 (hu)
JP (1) JP3152940B2 (hu)
KR (1) KR20000022516A (hu)
CN (1) CN1080260C (hu)
AP (1) AP1025A (hu)
AR (1) AR007456A1 (hu)
AT (1) ATE244713T1 (hu)
AU (1) AU716376B2 (hu)
BG (1) BG64052B1 (hu)
BR (1) BR9712782A (hu)
CA (1) CA2258285C (hu)
CO (1) CO4900056A1 (hu)
CZ (1) CZ423398A3 (hu)
DE (1) DE69723447T2 (hu)
DK (1) DK0912558T3 (hu)
DZ (1) DZ2254A1 (hu)
EA (1) EA002274B1 (hu)
ES (1) ES2201299T3 (hu)
GT (1) GT199700075A (hu)
HK (1) HK1018700A1 (hu)
HN (1) HN1997000079A (hu)
HR (1) HRP970350B1 (hu)
HU (1) HUP9903009A3 (hu)
ID (1) ID18579A (hu)
IL (1) IL127036A (hu)
IS (1) IS4910A (hu)
MA (1) MA24225A1 (hu)
MY (1) MY116915A (hu)
NO (1) NO986103D0 (hu)
NZ (1) NZ332752A (hu)
OA (1) OA10934A (hu)
PA (1) PA8432301A1 (hu)
PL (1) PL330974A1 (hu)
PT (1) PT912558E (hu)
SI (1) SI0912558T1 (hu)
SK (1) SK176598A3 (hu)
TN (1) TNSN97108A1 (hu)
TR (1) TR199802685T2 (hu)
TW (1) TW434237B (hu)
WO (1) WO1997049702A1 (hu)
YU (1) YU60198A (hu)
ZA (1) ZA975581B (hu)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997048697A1 (en) 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
YU11299A (sh) * 1996-09-04 2001-07-10 Pfizer Inc. Derivati indazola
US6248746B1 (en) 1998-01-07 2001-06-19 Euro-Celtique S.A. 3-(arylalkyl) xanthines
CA2309175A1 (en) * 1997-11-04 1999-05-14 Pfizer Products Inc. Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors
ATE290002T1 (de) * 1999-12-23 2005-03-15 Icos Corp Cyclische amp spezifische phosphodiesterase inhibitoren
US6362213B1 (en) 1999-12-23 2002-03-26 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
US7205320B2 (en) 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
US7153871B2 (en) 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US6982274B2 (en) * 2001-04-16 2006-01-03 Eisai Co., Ltd. 1H-indazole compound
PT1908463E (pt) 2001-12-14 2011-12-19 Merck Serono Sa Método para induzir a ovulação utilizando um modulador de nível camp não polipeptídico
BR0313000A (pt) 2002-07-19 2005-07-12 Memory Pharm Corp Compostos, composição farmacêutica e método para efetuar a inibição da enzima pde4, realçar a cognição e/ou tratar a psicose em um paciente
NZ537724A (en) 2002-07-19 2006-10-27 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs
BR0315705A (pt) * 2002-11-19 2005-09-06 Memory Pharm Corp Inibidores de fosfodiesterase-4
WO2004094411A1 (en) * 2003-04-18 2004-11-04 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
US20090048255A1 (en) * 2003-07-21 2009-02-19 Schumacher Richard A Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
WO2006044528A1 (en) * 2004-10-15 2006-04-27 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
WO2006129158A2 (en) * 2005-05-30 2006-12-07 Ranbaxy Laboratories Limited 3 - indazolyl - isoxazoline derivatives as inhibitors of phosphodiesterase type - i
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス,インコーポレイティド ムスカリン性受容体調節による神経発生
US7781460B2 (en) 2005-09-05 2010-08-24 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-IV
WO2007031838A1 (en) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
MX2009009793A (es) 2007-03-14 2009-10-16 Ranbaxy Lab Ltd Derivados de pirazolo (3,4-b) piridina como inhibidores de fosfodiesterasa.
US20100029689A1 (en) * 2008-07-02 2010-02-04 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
NZ599597A (en) * 2009-10-30 2013-05-31 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
WO2015166370A1 (en) 2014-04-28 2015-11-05 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
KR20220167441A (ko) * 2021-06-11 2022-12-21 주식회사 메타센테라퓨틱스 신규한 인돌 유도체 및 이의 최종당화산물 관련 질환의 치료 용도
KR20220167804A (ko) * 2021-06-11 2022-12-22 주식회사 메타센테라퓨틱스 인돌 유도체를 포함하는 최종당화산물 관련 질환의 치료용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB753573A (en) * 1953-06-17 1956-07-25 Ici Ltd New dyestuffs intermediates
GB8707051D0 (en) * 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
PT100441A (pt) * 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
TW223004B (hu) * 1991-11-25 1994-05-01 Sumitomo Chemical Co
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
AU677776B2 (en) * 1992-04-02 1997-05-08 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US5554620A (en) * 1993-09-14 1996-09-10 Sterling Winthrop Inc. Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof
JPH07215952A (ja) * 1993-12-06 1995-08-15 Otsuka Pharmaceut Factory Inc カテコール誘導体
WO1996012720A1 (en) * 1994-10-20 1996-05-02 Pfizer Inc. Bicyclic tetrahydro pyrazolopyridines and their use as medicaments

Also Published As

Publication number Publication date
MY116915A (en) 2004-04-30
CA2258285C (en) 2002-11-26
PL330974A1 (en) 1999-06-21
OA10934A (en) 2002-02-18
CZ423398A3 (cs) 1999-12-15
ATE244713T1 (de) 2003-07-15
MA24225A1 (fr) 1997-12-31
CO4900056A1 (es) 2000-03-27
EA002274B1 (ru) 2002-02-28
NZ332752A (en) 2001-04-27
PA8432301A1 (es) 1999-12-27
HK1018700A1 (en) 1999-12-30
HN1997000079A (es) 1997-12-26
TW434237B (en) 2001-05-16
YU60198A (sh) 1999-09-27
AR007456A1 (es) 1999-10-27
PT912558E (pt) 2003-11-28
HRP970350B1 (en) 2003-04-30
IS4910A (is) 1998-11-27
BR9712782A (pt) 1999-12-07
US6040329A (en) 2000-03-21
JP3152940B2 (ja) 2001-04-03
NO986103L (no) 1998-12-23
JPH11514668A (ja) 1999-12-14
DK0912558T3 (da) 2003-08-18
GT199700075A (es) 1998-12-04
DZ2254A1 (fr) 2002-12-18
BG64052B1 (bg) 2003-11-28
ID18579A (id) 1998-04-23
AP1025A (en) 2001-11-19
HUP9903009A3 (en) 2002-01-28
EA199801047A1 (ru) 1999-06-24
WO1997049702A1 (en) 1997-12-31
NO986103D0 (no) 1998-12-23
TR199802685T2 (xx) 1999-03-22
HRP970350A2 (en) 1998-06-30
SI0912558T1 (en) 2003-10-31
DE69723447D1 (de) 2003-08-14
EP0912558A1 (en) 1999-05-06
AU716376B2 (en) 2000-02-24
ES2201299T3 (es) 2004-03-16
AP9701020A0 (en) 1997-07-31
CA2258285A1 (en) 1997-12-31
CN1223651A (zh) 1999-07-21
DE69723447T2 (de) 2003-12-24
ZA975581B (en) 1998-12-24
IL127036A (en) 2001-06-14
AU2785797A (en) 1998-01-14
CN1080260C (zh) 2002-03-06
SK176598A3 (en) 2000-06-12
EP0912558B1 (en) 2003-07-09
TNSN97108A1 (fr) 2005-03-15
KR20000022516A (ko) 2000-04-25
IL127036A0 (en) 1999-09-22
BG103056A (en) 1999-10-29

Similar Documents

Publication Publication Date Title
HUP9903009A2 (hu) Szubsztituált indazolszármazékok és IV típusú foszfodiészteráz (PDE) és tumornekrózis faktor (TNF) inhibítorokként történő alkalmazásuk
HUP9901780A2 (hu) Foszforidészteráz, illetve tumor nekrózis faktor gátló hatású imid-származékok, valamint ezeket a vegyületeket tartalmazó gyógyászati készítmények
HUP9902459A2 (hu) Szubsztituált indazolszármazékok és felhasználásuk IV-típusú foszfodiészteráz (PDE) aktivitásának, és a tumornekrózis-faktor (TNF) keletkezésének gátlására
ATE250582T1 (de) Chinolinderivate als mek enzym-inhibitoren
DE69131581D1 (de) 2-Oxindolderivate als Tyrosinekinaseinhibitoren
NO159656C (no) Analogifremgangsm te til fremstilling av terapeutisk aktive karbapenemderivater.
HUP9802822A2 (hu) Halogén-benzimidazol-származékok, intermedierjeik, előállításuk és a vegyületeket hatóanyagként tartalmazó mikrobicid készítmények
ES2001936A6 (es) Procedimiento para la preparacion de indoles sustituidos con heterociclos.
FI963238A0 (fi) Heteroaromaattisia oksatsoli yhdisteitä ja niiden käyttö
DK0528337T3 (da) Thiazolylbenzofuranderivater, fremgangsmåde til fremstilling deraf og farmaceutiske præparater, der indeholder disse forbin
IL164487A0 (en) 3-Heteroaryl substituted 5-methyloxymethyl isoxazolines used as herbicides
ATE164575T1 (de) Substituierte aromatische verbindungen als c. amp phosphodiesterase-und tnf-hemmer
DK0409406T3 (da) Arylsubstituerede aminderivater, der er anvendelige ved cancerterapi
IL146326A0 (en) Quinoline derivatives as inhibitors of mek enzymes
HUP0002300A2 (hu) 4-Kinolinkarboxamid-származékok, előállításuk, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
HUP0004477A2 (hu) Herbicid hatású 3-(1,2-benzizotiazol- vagy-izoxazol-5-il)-csoporttal helyettesített pirimidinszármazékok, intermedierjeik, előállításuk és alkalmazásuk
TW429255B (en) Pyrazine compounds having treatment of central nervous system diseases and disorders
HUP0004855A2 (hu) Eljárás kinolinszármazékok előállítására és az eljárás intermedierjei
NO171786C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive isokinolinderivater
NZ505596A (en) Fungicidal mixtures based on amide compounds and morpholine or piperidine derivatives
HUP0100777A2 (hu) Növekedési hormont felszabadító tripeptidek, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
NO159269C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive heterocykliske fenylamidiner.
ATE228120T1 (de) Biphenylsulfonylarylcarbonsäuren verwendbar zur behandlung von insulin resistenz und hyperglycemia
DK48188A (da) Ergolinyl-heterocycliske forbindelser og fremgangsmaade til fremstilling deraf
HUP9900895A2 (hu) Simaizom sejtburjánzást gátló 2-szubsztituált benzimidazolszármazékok

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees